[Place of innovative therapies in the management of cervical cancer]

Abstract

Despite optimized screening and prevention strategies, cervical cancer remains a major public health problem, even in developed countries. In France, the incidence is estimated at 3159 cases per year in 2023. While the management of early-stage cases is now highly standardized, few therapeutic advances were made in the treatment of metastatic stages before 2021, before the therapeutic arsenal that we know today took off. The aim of this review is to summarize these advances.

Keywords: Anticorps drogue conjugués; Cancer du col; Cervical cancer; Drug-conjugated antibodies; Immunotherapy; Immunothérapie; Innovations thérapeutiques; Targeted therapies; Therapeutic innovations; Thérapies ciblées.